Retinal Vein Occlusions(RVO)

Also known as: Retinal Vein Occlusion / Retinal Vein Occlusions / Retinal Vein Occlusion (RVO) / Vein Occlusions, Retinal / Occlusion retinal vein

DrugDrug NameDrug Description
DB08885AfliberceptAflibercept is a recombinant fusion protein that comprises of two main components: the vascular endothelial growth factor (VEGF) binding portions from the extracellular domains of human VEGF receptors 1 and 2 which is then fused to the Fc portion of human IgG1. Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012.
DB01270RanibizumabRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DrugDrug NamePhaseStatusCount
DB01270Ranibizumab1Completed1
DB01270Ranibizumab1Terminated1
DB01270Ranibizumab1Unknown Status1
DB00620Triamcinolone1Completed2
DB08885Aflibercept1 / 2Completed1
DB00112Bevacizumab1 / 2Completed1
DB01234Dexamethasone1 / 2Completed1
DB01017Minocycline1 / 2Recruiting2
DB01270Ranibizumab1 / 2Completed3
DB06461Squalamine1 / 2Completed1
DB08885Aflibercept2Recruiting1
DB05288Anecortave acetate2Withdrawn1
DB12460Conbercept2Unknown Status1
DB00869Dorzolamide2Completed1
DB00591Fluocinolone acetonide2Terminated1
DB04895Pegaptanib2Completed1
DB01270Ranibizumab2Completed1
DB01270Ranibizumab2Unknown Status1
DB00373Timolol2Completed1
DB00112Bevacizumab2 / 3Recruiting2
DB01234Dexamethasone2 / 3Completed1
DB08162Fasudil2 / 3Recruiting1
DB00627Niacin2 / 3Completed1
DB00860Prednisolone2 / 3Completed1
DB01270Ranibizumab2 / 3Recruiting1
DB00945Acetylsalicylic acid3Terminated1
DB08885Aflibercept3Completed1
DB01076Atorvastatin3Unknown Status1
DB00112Bevacizumab3Completed2
DB11121Chloroxylenol3Terminated2
DB01234Dexamethasone3Completed2
DB01234Dexamethasone3Unknown Status1
DB01109Heparin3Terminated1
DB09260Parnaparin3Terminated1
DB01270Ranibizumab3Completed5
DB00620Triamcinolone3Completed2
DB08885Aflibercept4Completed1
DB08885Aflibercept4Not Yet Recruiting1
DB08885Aflibercept4Unknown Status1
DB00126Ascorbic acid4Not Yet Recruiting2
DB00112Bevacizumab4Completed1
DB11136Chromium4Not Yet Recruiting2
DB01234Dexamethasone4Completed3
DB06757Manganese4Not Yet Recruiting2
DB00968Methyldopa4Not Yet Recruiting2
DB04895Pegaptanib4Recruiting1
DB01270Ranibizumab4Completed4
DB11135Selenium4Not Yet Recruiting2
DB01593Zinc4Not Yet Recruiting2
DB08885AfliberceptNot AvailableActive Not Recruiting1
DB08885AfliberceptNot AvailableCompleted2
DB00112BevacizumabNot AvailableCompleted2
DB01234DexamethasoneNot AvailableCompleted6
DB00873LoteprednolNot AvailableCompleted1
DB01270RanibizumabNot AvailableCompleted4
DB01270RanibizumabNot AvailableUnknown Status1